Skip to main
GOSS

GOSS Stock Forecast & Price Target

GOSS Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 60%
Buy 40%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Gossamer Bio Inc. is benefiting from exceptionally positive sentiment among key opinion leaders (KOLs), particularly regarding the anticipated success of its pulmonary arterial hypertension (PAH) treatment, PROSERA, which is expected to demonstrate significant treatment effects. The Phase 2 TORREY data highlighted consistent benefits in multiple endpoints, showcasing the drug's potential efficacy, safety, and durability, thus strengthening the company's standing in the competitive biopharmaceutical landscape. Additionally, renewed investor interest stemming from recent conferences and optimistic discussions surrounding Gossamer Bio's pipeline further underpins the positive outlook for the company's stock.

Bears say

Gossamer Bio has a negative outlook primarily due to the market's mispricing of seralutinib's probability of success, which suggests an overestimation of the asset's value despite recent stock appreciation. The lack of concrete financial progress or regulatory advancement for the pipeline products raises concerns about the viability of the company's strategic focus in therapeutics. Additionally, the continued uncertainty surrounding seralutinib’s clinical development could adversely affect investor confidence and the company's long-term financial stability.

GOSS has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 60% of analysts recommend a Strong Buy, 40% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Gossamer Bio Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Gossamer Bio Inc (GOSS) Forecast

Analysts have given GOSS a Strong Buy based on their latest research and market trends.

According to 5 analysts, GOSS has a Strong Buy consensus rating as of Dec 31, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8.60, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8.60, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Gossamer Bio Inc (GOSS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.